| Valuation |
8.5 |
auto |
P/E 38.1 |
| Liquidity |
8.4 |
auto |
Current ratio 1.58 |
| Growth |
10.0 |
auto |
Revenue growth 42.6% |
| Profitability |
10.0 |
auto |
Net margin 31.7% |
| Efficiency |
10.0 |
auto |
ROE 101.2% |
| Leadership Tenure |
8.5 |
ai |
David Ricks has been CEO since January 2017 (~8 years), with deep continuity and a clean executive bench; he has overseen LLY's transformation into the obesity/diabetes leader but is a competent corporate executive rather than an iconic founder, so no +1 boost. |
| Ownership Alignment |
4.2 |
auto |
Insider holding 0.17% |
| Strategic Vision |
9.5 |
ai |
Clear, ambitious 10+ year roadmap stacking GLP-1 leadership (Mounjaro/Zepbound), next-gen obesity (orforglipron oral, retatrutide triple-agonist), Alzheimer's (Kisunla), and oncology (Verzenio), with massive manufacturing capex buildout in Indiana/NC/Germany to support it. |
| Focus / Clarity |
8.7 |
ai |
Tightly focused pure-play pharma anchored on diabetes/obesity, immunology, neuroscience, and oncology — coherent therapeutic-area strategy with no consumer or medtech distractions. |
| Diversification |
7.4 |
ai |
Revenue is increasingly concentrated in incretin franchise (Mounjaro + Zepbound now >40% of sales and growing), though the company sells globally with diversified payers and a broad pipeline across CV, Alzheimer's, and oncology providing optionality. |
| Maturity / Revenue |
9.6 |
ai |
Revenue $65.2B |
| Growth Potential |
9.7 |
ai |
Obesity TAM estimated $150-200B+ by 2030 with sub-10% current penetration; LLY is the clear co-leader with Novo, plus optionality from oral GLP-1 (orforglipron), Alzheimer's, and oncology — multiple secular tailwinds compounding. |
| Volatility |
5.7 |
auto |
β 0.50 · D/E 165.31 |
| Market Standing |
9.3 |
auto |
Market cap $780.8B |
| Competitive Moat |
9.4 |
ai |
Effective duopoly with Novo Nordisk in GLP-1 (>40% share of a category becoming essential), strong IP on tirzepatide, multi-billion manufacturing capacity moat that competitors cannot replicate quickly, and R&D >25% of revenue — strong stack but not yet at the NVDA/ASML best-in-industry +1 tier given Novo's parity. |